Millipore Sigma Vibrant Logo

474791 InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem

InSolution™ MG-132, CAS 133407-82-6, is provided as a 10 mM solution in DMSO. Acts as a potent, reversible proteasome inhibitor (Ki = 4 nM).

Ficha de dados de segurança do material (FDSM) ou ficha de segurança do material (FSM), certificado de análise (CA) e certificado de qualidade (CQ), dossiês e outros documentos disponíveis.

Sinônimos: Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI

Primary Target: proteasome
View Products on Sigmaaldrich.com
474791
Ver preços e disponibilidade

Panorama geral

Replacement Information

Tabela com principais espec.

CAS #Empirical Formula
133407-82-6C₂₆H₄₁N₃O₅

Preço e Disponibilidade

Número de catálogo DisponibilidadeEmbalagem Qtde/Emb. Preço Quantidade
474791-1MG
Verificando a disponibilidade...
—
Disponibilidade limitada Disponibilidade limitada
Insira quantidade 
Descontinuado
Quantidades limitadas disponíveis
Disponibilidade a ser confirmada
    Restante: será informado
      Restante: será informado
      Vai informar
      Contatar o serviço de atendimento ao cliente
      Contact Customer Service

      		 Ampola plástica 1 mg
      Recuperando preço...
      O preço não pôde ser recuperado
      Quantidade mínima necessária para ser múltipla de
      Maximum Quantity is
      Após finalização do pedido Mais informações
      Você salvou ()
       
      —
      Solicitar preço
      		 —
      Description
      Catalogue Number474791
      Brand Family Calbiochem®
      SynonymsCarbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
      References
      ReferencesMeriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
      Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
      Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
      Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
      Read, M.A., et al. 1995. Immunity 2, 493.
      Rock, K.L., et al. 1994. Cell 78, 761.
      Product Information
      CAS number133407-82-6
      ATP CompetitiveN
      FormLiquid
      FormulationA 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
      Hill FormulaC₂₆H₄₁N₃O₅
      Chemical formulaC₂₆H₄₁N₃O₅
      ReversibleY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetproteasome
      Primary Target IC<sub>50</sub>3 µM in inhibiting NF-κB activation
      Primary Target K<sub>i</sub>4 nM as proteasome inhibitor
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 36/38

      Irritating to eyes and skin.
      S PhraseS: 26-36-45

      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Irritant
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de catálogo GTIN
      474791-1MG 04055977185515

      Documentation

      InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem MSDS

      Título

      Ficha de Segurança de Produtos (MSDS) 

      InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem Certificados de análise

      TítuloNúmero do lote
      474791

      Referências

      Visão geral de referência
      Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
      Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
      Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
      Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
      Read, M.A., et al. 1995. Immunity 2, 493.
      Rock, K.L., et al. 1994. Cell 78, 761.

      Brochura

      Título
      Caspases and other Apoptosis Related Tools Brochure

      Citações

      Título
    • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
    • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
    • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
    • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
    • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
    • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
    • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
    • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
    • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
    • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
      		•
      Ficha de dados

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision03-June-2013 JSW
      SynonymsCarbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
      DescriptionPotent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable stains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1) and inhibits NF-κB activation (IC50 = 3 µM).
      FormLiquid
      FormulationA 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number133407-82-6
      Chemical formulaC₂₆H₄₁N₃O₅
      Purity≥98% by HPLC
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Irritant
      ReferencesMeriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
      Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
      Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
      Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
      Read, M.A., et al. 1995. Immunity 2, 493.
      Rock, K.L., et al. 1994. Cell 78, 761.
      Citation
    • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
    • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
    • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
    • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
    • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
    • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
    • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
    • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
    • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
    • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
      		•